SmithKline Nicoderm patch aids Tourette's syndrome drug efficacy -- case report.
This article was originally published in The Tan Sheet
Executive Summary
NICODERM PATCH BOOSTS TREATMENT DRUG EFFECTIVENESS IN CHILDREN WITH TOURETTE's syndrome a case study of 16 young patients published in the December Journal of the American Academy of Child and Adolescent Psychiatry. Adding SmithKline Beecham's 7 mg Nicoderm transdermal nicotine patch to patients' pre-existing drug therapy resulted in "significant reduction in motor and vocal tics and improvement in overall adjustment for 13 of the 16 patients," Archie Silver, MD, et al., University of South Florida, reported. The study was partially funded by the National Institute of Neurological Disorders & Stroke and the Smokeless Tobacco Research Council.